Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
Moderna sees up to $15 bln in respiratory vaccine sales in 2027
Moderna is testing vaccines against respiratory syncytial virus (RSV), influenza and a new generation COVID-19 shot in late-stage studies.
- By Reuters
- New Delhi
- Apr 12, 2023
Moderna Inc said on Tuesday it expects sales from its respiratory vaccines to be between $8 billion and $15 billion in 2027.
The company said ahead of its annual vaccines conference on Tuesday that it expects to launch six major vaccines in the next few years.
Moderna is testing vaccines against respiratory syncytial virus (RSV), influenza and a next-generation COVID-19 shot in late-stage studies.